Michael Thomas Henderson, chief executive officer of both Apogee Therapeutics (APGE) and Spyre Therapeutics (SYRE), has been a consistent seller of company stock over the past year, with no open-market purchases recorded in his 43 total Form 4 transactions. The aggregate value of his sales reached approximately $36.3 million, concentrated entirely in the last several months. The most recent activity shows a continuation of this pattern: on July 8, 2026, he sold APGE shares worth about $2.67 million, following a much larger $10.6 million sale on June 22. That same day, he also disposed of $2 million in SYRE stock. His June 10 APGE transactions were particularly active, comprising six separate sales totaling roughly $1.67 million, with individual amounts ranging from about $53,000 to $634,000.
The selling bias is unambiguous across both companies. In May, Henderson executed four SYRE sales on May 8 worth a combined $5.95 million, and he sold APGE shares on May 13 for approximately $1.64 million. April brought another cluster of APGE sales on April 8 totaling about $1.65 million, plus a small $17,000 sale, alongside an option exercise (code M) valued at $68,580 on April 16. March and February saw additional APGE sales of roughly $1.5 million and $62,000, respectively. Notably, the only non-sale transactions were a gift of APGE shares on July 10 (valued at $0) and an equity award (code A) of SYRE stock on May 27, both of which are compensatory or non-monetary in nature rather than discretionary purchases. Across all 43 filings, Henderson has never acquired shares through an open-market buy, making his disposition of roughly $36 million in stock a clear and sustained divestment trend.
AI-assisted summary